Zero to Hero? Scope 3 Emissions – A Strategic Imperative for Pharma Companies Verena Ahnert Read more
Executive Insights Life Sciences & Pharma Combination Vaccines: Converting Clinical Promise Into Commercial Scale July 11, 2025
Executive Insights Healthcare The Race Is On: Winning Smart in the Intensifying GLP-1 Market in China May 15, 2025
Executive Insights Life Sciences & Pharma When Is It Too Late? Drivers of Commercial Performance for Late Entrants in Biopharma April 28, 2025
Executive Insights Life Sciences & Pharma Transitioning to EU-Wide Health Technology Assessments: Implications for Pharma April 14, 2025
Executive Insights Digital Your AI Transformation Needs a Different Leadership Approach March 7, 2025